Literature DB >> 12934194

Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia.

Catherine Greene1, Clifford Taggart, Gregory Lowe, Paula Gallagher, Noel McElvaney, Shane O'Neill.   

Abstract

Protease-antiprotease balance in 17 patients with unilateral community-acquired pneumonia (CAP) was characterized (day 6+/-0.8). Levels and activities of alpha-1 antitrypsin (A1AT), secretory leucoprotease inhibitor (SLPI), and neutrophil elastase (NE) were quantified. Lobes were designated as infected or uninvolved according to the presence of an infiltrate on chest radiograph. NE levels in infected lobes were higher than those in uninvolved lobes, and NE levels were significantly elevated in both, compared with that in control lobes (n=18; P<.01). A1AT and SLPI levels were similar in infected and uninvolved lobes and were significantly elevated, compared with those in control lobes (P<.05 and P<.005, respectively). Anti-NE activity in infected lobes was less than that in control or uninvolved lobes (P<.05); values in the latter 2 were similar. Free NE was detected in 7 of the infected samples, indicating that anti-NE capacity is impaired. Both A1AT and SLPI were cleaved or complexed in infected lobes, and A1AT was oxidized in infected lobes. We conclude that mean elastase levels are increased and that mean anti-elastase capacity is decreased in pneumonic lobes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934194     DOI: 10.1086/377238

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Differences in innate immune response gene regulation in the middle ear of children who are otitis prone and in those not otitis prone.

Authors:  Ravinder Kaur; Janet Casey; Michael Pichichero
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

3.  Proteomic analysis of cerebrospinal fluid in pneumococcal meningitis reveals potential biomarkers associated with survival.

Authors:  Upali R Goonetilleke; Matthew Scarborough; Stephen A Ward; Stephen B Gordon
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

4.  Two-dimensional gel electrophoresis analysis in simultaneous influenza pneumonia and bacterial infection in mice.

Authors:  K Kosai; M Seki; K Yanagihara; S Nakamura; S Kurihara; Y Imamura; K Izumikawa; H Kakeya; Y Yamamoto; T Tashiro; S Kohno
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

5.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

6.  Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.

Authors:  Murali Shyamsundar; Scott T W McKeown; Cecilia M O'Kane; Thelma R Craig; Vanessa Brown; David R Thickett; Michael A Matthay; Clifford C Taggart; Janne T Backman; J Stuart Elborn; Daniel F McAuley
Journal:  Am J Respir Crit Care Med       Date:  2009-03-26       Impact factor: 21.405

7.  Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.

Authors:  Catherine M Greene; Noel G McElvaney; Shane J O'Neill; Clifford C Taggart
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 8.  Antimicrobial proteins and polypeptides in pulmonary innate defence.

Authors:  Mark P Rogan; Patrick Geraghty; Catherine M Greene; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Respir Res       Date:  2006-02-17

9.  Increase in net activity of serine proteinases but not gelatinases after local endotoxin exposure in the peripheral airways of healthy subjects.

Authors:  Margaretha E Smith; Steven Bozinovski; Carina Malmhäll; Margareta Sjöstrand; Pernilla Glader; Per Venge; Pieter S Hiemstra; Gary P Anderson; Anders Lindén; Ingemar Qvarfordt
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Emerging pharmacological therapies for ARDS: COVID-19 and beyond.

Authors:  Shahd Horie; Bairbre McNicholas; Emanuele Rezoagli; Tài Pham; Ger Curley; Danny McAuley; Cecilia O'Kane; Alistair Nichol; Claudia Dos Santos; Patricia R M Rocco; Giacomo Bellani; John G Laffey
Journal:  Intensive Care Med       Date:  2020-07-11       Impact factor: 41.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.